We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Survey Reveals Large Number of Prion Carriers in the United Kingdom

By LabMedica International staff writers
Posted on 28 Oct 2013
Print article
Image: Light photomicrograph of brain tissue reveals the presence of typical amyloid plaques found in a case of variant Creutzfeldt-Jakob disease (vCJD). Magnified 158x, and stained by the H&E (hematoxylin and eosin) staining technique (Photo courtesy of the US Centers for Disease Control (CDC)).
Image: Light photomicrograph of brain tissue reveals the presence of typical amyloid plaques found in a case of variant Creutzfeldt-Jakob disease (vCJD). Magnified 158x, and stained by the H&E (hematoxylin and eosin) staining technique (Photo courtesy of the US Centers for Disease Control (CDC)).
A second immunohistochemistry survey of archived appendix samples conducted in the United Kingdom has found that the number of individuals carrying variant Creutzfeldt-Jakob disease prions was more than double that found in the first survey.

Variant Creutzfeldt-Jakob disease (vCJD) is a prion disease that was first described in 1996 in the United Kingdom. Scientific evidence has shown that the agent responsible for the outbreak of prion disease in cows, bovine spongiform encephalopathy (BSE or "mad cow” disease), is the same agent responsible for the outbreak of vCJD in humans. Both disorders are invariably fatal brain diseases with unusually long incubation periods measured in years, and are caused by an unconventional transmissible agent called a prion. vCJD is not the same disease as classic CJD, which has different clinical and pathologic characteristics.

Although there have been only 177 clinical cases of vCJD to date in the United Kingdom, previous studies have estimated that around one in 4,000 people may carry vCJD prions. To confirm this estimate, investigators at the Institute of Neurology of University College London (United Kingdom) tested 32,441 archived appendix samples fixed in formalin and embedded in paraffin (FFPE) for the presence of abnormal prion protein (PrP).

They identified 16 appendix samples positive for abnormal PrP, indicating an overall prevalence of 493 per million. From this figure, the investigators estimated that one in 2,000 people were likely to be carriers.

The prevalence of the prion in those born in 1941-60 (733 per million, 269 to 1596 per million) did not differ significantly from those born between 1961 and 1985 (412 per million, 198 to 758 per million) and was similar in both sexes and across the three broad geographical areas sampled.

Genetic testing of the 16 positive samples revealed a higher proportion of the valine homozygous (VV) genotype on the codon 129 of the gene encoding the prion protein (PRNP) compared with the general population of the United Kingdom. This genotype also differed from the 177 patients with vCJD, all of whom displayed the methionine homozygous (MM) genotype.

The investigators concluded that, "This study corroborates previous studies and suggests a high prevalence of infection with abnormal PrP, indicating vCJD carrier status in the population compared with the 177 vCJD cases to date. These findings have important implications for the management of blood and blood products and for the handling of surgical instruments."

The study was published in the October 15, 2013, online edition of the British Medical Journal.

Related Links:

University College London



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Thyroid Stimulating Hormone Assay
Neonatal TSH ELISA Kit
New
Control Material
Blood Culture Identification Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.